HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical- stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for current good manufacturing practice (cGMP) manufacturing of MT-601, Marker's lead Multi-Antig ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new clinical and preclinical data from its pipeline of gamma-delta T cell therapies at several upcoming scientific conferences. "The breadth of data we're presenting at upcoming medical conferences reflects the scientific rigor and clinical potential of IN8bio's gamma-de ...

Core Insights - Marker Therapeutics, Inc. is participating in Canaccord Genuity's Horizons in Oncology Virtual Conference, focusing on innovations in T cell-based immunotherapies for cancer treatment [1][2]. Company Overview - Marker Therapeutics is a clinical-stage immuno-oncology company based in Houston, TX, specializing in next-generation T cell-based immunotherapies for hematological malignancies and solid tumors [5]. - The company was founded at Baylor College of Medicine and has conducted clinical trials involving over 200 patients, demonstrating that its autologous and allogeneic MAR-T cell products are well tolerated and show durable clinical responses [5]. - The company aims to introduce novel T cell therapies to the market while prioritizing financial resource preservation and operational excellence [5]. Panel Discussion Details - Dr. Juan Vera, CEO of Marker Therapeutics, will participate in a panel titled "CAR-T in Solid Tumors and New T-cell Approaches – Breakthroughs Ahead?" on April 7, 2025, from 11:00 AM to 11:50 AM ET [3]. - The panel will include discussions on the future of CAR-T therapies and other novel approaches in treating solid tumors [2][3]. Technology and Innovation - Marker Therapeutics is advancing a unique multi antigen recognizing (MAR)-T cell therapy platform designed to target multiple tumor-associated antigens simultaneously, showing promising clinical results in both hematologic malignancies and solid tumors [3].